Deep Longevity and SquareOne Wellness partner on deep biomarkers of aging and longevity

Deep Longevity added SquareOne Wellness to its growing longevity network; SquareOne physicians will get training in longevity medicine and interpret the AgeMetric™ reports incorporating multiple aging clocks

Today, Deep Longevity Inc, a pioneer in deep biomarkers of aging and longevity, and SquareOne Wellness announced a collaboration to deploy an extensive range of AI-powered aging clocks. Deep Longevity is to develop and provide the customized predictors of human biological age to the network of SquareOne Wellness clinicians and to provide a training program in longevity medicine.

Deep Longevity is a fully-owned subsidiary of a public company, Regent Pacific Group Limited (SEHK:0575.HK). Deep Longevity developed and exclusively in-licensed a portfolio of granted and pending patents on aging clocks developed using the latest advances in artificial intelligence.

Deep Longevity aging clocks are supported by a number of academic publications summarized in a recent review titled "BioHorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities"

"The traditional approach to preventative medicine is focused on preventing disease by diagnosing the symptoms early or reducing the risks of disease. The AI-guided longevity medicine goes much further then that and is focusing on tracking the person's rates of aging at many levels, identification of longevity bottlenecks, and utilizing the latest advances in science and technology to slow down or reverse biological and psychological aging. We are very happy to have SquareOne join the rapidly growing network of our research and clinical partners focused on providing customers with extra years of productive and happy life", said Alex Zhavoronkov, Chief Longevity Officer of Deep Longevity Inc. 

SquareOne Wellness has been on the forefront of total wellness in the treatment of addiction. SquareOne has a holistic approach to wellness and addiction whose goal is to help patients live happier, healthier and longer lives. Deep Longevity and SquareOne will partner to see the impact that the utilization of aging clocks has on continued recovery. "We are always looking for new tools to help our patients reach their full potential in their recovery and in their overall health and life. We believe that the addition of deep aging clocks will be an added tool in long term patient success", said Joshua Jones, Director of Patient Interactions of SquareOne Wellness.

In the scope of the partnership SquareOne Wellness physicians will be trained in deep aging clocks and will be able to provide their customers with AgeMetric™ reports and engage in advanced research to assess the performance of aging clocks in the context of continued recovery.

###

About Regent Pacific (SEHK:0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

http://www.regentpac.com/

About SquareOne Wellness.

SquareOne Wellness is an addiction and wellness clinic that focuses on recovery of opioid addiction and behavioral health. SOW focus is on helping patients look at every aspect of their health utilizing medically assisted treatment, behavioral health therapy and lifestyle changes to help sustain recovery and live healthier and longer lives. For more information, visit Squareonewellness.org.

About Deep Longevity, Inc

Deep Longevity has been acquired by Regent Pacific (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other experts AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of

the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.

http://longevity.ai/

Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery

Insilico partners with Taisho Pharmaceutical on end-to-end AI-powered senolytic drug discovery. Leading Japanese pharmaceutical company to engage Insilico Medicine on research partnership in the discovery of novel molecules

Thursday, October 15, 2020 (9 am ET) - Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its proprietary Pandomics Discovery Platform to identify novel targets for senolytic drugs and Chemistry42 platform for a molecular generation. This collaboration brings together Insilico's state-of-art artificial intelligence (AI) technologies in drug discovery with Taisho's expertise in drug development, aimed to extend the human healthspan.

'We're delighted to collaborate with Taisho pharmaceutical, a well-recognized leader in the pharmaceutical industry and healthcare sector. It is believed that aging is a universal phenomenon that we cannot stop. However, emerging scientific evidence has shown that one may be able to reverse some of the age-associated processes. Through this collaboration, we will adopt our AI-powered drug discovery suites together with Taisho's validation platform to explore the new space of anti-aging solutions', said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan, a fully-owned subsidiary of Insilico Medicine

Under the terms of the agreement, Insilico Medicine will receive an upfront payment and milestone payments upon achievement of specified goals. Insilico Medicine will be responsible for early research phase target identification and molecular generation and Taisho will work collaboratively with Insilico in validating the results in various in vitro and in vivo assays. Taisho has the exclusive option to acquire Insilico's co-ownership of the successfully developed programs under agreed payment.

'It is our great honor to be collaborating with the scientists of Taisho Pharmaceutical, one of the top 100 pharmaceutical companies in the world operating since 1912. The high level of the scientists we are interfacing, and our previous successes in the application of the Pharma.AI platform for discovery of novel targets and molecules in fibrosis, and previous experience in senolytic drug discovery give us confidence that this collaboration will be successful', said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

###

About Taisho Pharmaceutical Co., Ltd.

https://www.taisho.co.jp/global/

Media Contact

For further information, images or interviews, please contact: ai@insilico.com

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/

Insights from the largest conference on aging research and drug discovery revealed

The 4-day, 7th Aging Research, and Drug Discovery on-site and online conference organized by the University of Copenhagen, Columbia University, and Deep Longevity scientists attracted over 2,500 delegates

 Wednesday, September 30th, Copenhagen, Denmark -- The laboratory of the biology of aging at the University of Copenhagen, is happy to reveal the online availability of the lectures from the 7th Aging Research, and Drug Discovery (ARDD2020) on-site and online conference organized by the University of Copenhagen, Columbia University, and Deep Longevity scientists. The consented video lectures are available at http://www.AgingPharma.org. 

"It took a small village to be able to complete our Aging Research and Drug Discovery meeting. Huge thanks to everyone at Insilico Medicine and Deep Longevity as well as my co-organizers Alex Zhavoronkov and Daniela Bakula. Also thanks to the CESA staff who helped with the local arrangements. Without all these people the conference would not have reached the level that we did. As a final note, I want to encourage everyone to keep a lookout for next year's meeting. This time hopefully we will be able to meet in person at Columbia University, New York City. ", said Morten Scheibye-Knudsen, MD, Ph.D., the chair of the 7th Aging Research, and Drug Discovery, and head of the biology of the aging laboratory at the center for healthy aging at the University of Copenhagen. 

In 2020 the conference brought together over 2,500 registered delegates from academia, industry, and the government over 4 days with over 70 speakers and panelists. 

"We believe that this is the largest aging research meeting focusing on drug discovery and development to date. I am very happy to see that over the past 7 years since we started the meeting in Basel, it has grown and the longevity industry has evolved, matured, and gained the attention of the pharmaceutical companies and the governments worldwide. Healthy longevity is a fundamental human need and we need to dramatically expand the industry to make people live longer and healthier", said Alex Zhavoronkov, Ph.D., co-founder of ARDD, CEO of Insilico Medicine, and Chief Longevity Officer of Deep Longevity. 

###

About 7th Annual Aging Research and Drug Discovery (ARDD)

The Annual Aging Research and Drug Discovery (ARDD) Conference is an annual scientific conference bringing together academic, government, and industry thought leaders in aging research and longevity biotechnology. Started in 2014 as part of MipTec and later as part of Basel Life Science Week in Basel, Switzerland, the conference grew over the years to become the largest academic and industry meeting spanning 4 days with over 2,500 delegates in 2020 chaired by Morten Scheibye-Knudsen, MD, Ph.D., Daniela Bakula, Ph.D., of the University of Copenhagen and Alex Zhavoronkov, Ph.D. of Deep Longevity and Insilico Medicine. The conference is different from the other events in the field as it focuses on the translational aspect of aging research and has substantial participation from the large pharmaceutical and biotechnology companies and leading clinical centers. In the past, executives from Novartis, Roche, Regeneron, and many other pharmaceutical companies presented their research in aging. The conference materials are available at http://www.AgingPharma.org.